Best MR Reporting Software in India: An Honest Comparison

Search "best MR reporting software in India" and you get two kinds of result. Directory listings, which rank well and tell you little. And vendor blog posts declaring themselves the winner — one is literally titled "SEFMED Leads the Market." Ours could just as easily say RouteX does.

Neither helps the person actually doing the evaluation: a sales head with 40 to 400 MRs, a board asking why coverage slipped last cycle, and three vendors who all demo beautifully.

So this is the article we wish had existed. It covers what MR reporting software has to do in the Indian context specifically, why the global enterprise standard rarely wins here, what six platforms are each built for, and roughly what they cost.

What MR reporting software actually has to do in India

Every vendor's feature list looks similar. The reason they behave so differently in the field is that Indian pharma has requirements most global CRM platforms were never designed around.

The daily call report, and the 10pm ritual it creates

The DCR is the spine of Indian pharma field reporting. In principle it captures each doctor and chemist visit as it happens. In practice, on most systems, MRs fill it from memory late in the evening — because the tool made in-visit capture slower than remembering. That single behavioural failure poisons everything downstream: coverage numbers that describe recall rather than reality, and managers reviewing fiction with confidence.

The test is not whether a platform has DCR. All of them do. It is whether filing it during the visit is genuinely faster than filling it at 10pm.

Tour plans, beat plans and the approval chain

Indian field forces work to a monthly cycle built around planned beats. The plan is submitted, reviewed by an ASM or RSM, and approved or sent back. That approval step is not administrative decoration — it is where a manager catches a plan that under-covers the doctors who actually write prescriptions. A system where plans are recorded but never gated turns the cycle into a formality.

RCPA — the capability global platforms don't have

Retail Chemist Prescription Audit is close to unique to the Indian subcontinent. The MR stands at the chemist counter and records what is actually moving: your brand, the competitor's brand, volumes, and any scheme running against you. It exists because Indian prescription data is not centrally available the way dispensing data is in regulated Western markets — so the chemist counter becomes the measurement point.

This is the single clearest reason a globally dominant CRM can be the wrong tool in India. RCPA is not a feature those platforms skipped; it is a practice that does not exist in the markets they were built for.

Coverage against target, not activity logged

This is the distinction that separates reporting from management. Consider two numbers from the same cycle:

Most platforms report activity well. Fewer set a target per doctor grade at the start of the cycle and show live deviation from it. When you are evaluating, this is the question that produces the most revealing demo.

Samples, gifts and expenses

Sample and gift distribution needs a defensible record. Expenses need to derive from something verifiable — actual recorded travel rather than a number typed into a form at month end, which is where reconciliation disputes come from.

Three families of platform, and why the distinction decides your shortlist

Everything on an Indian shortlist comes from one of three lineages. They are not variations of the same product — they were built to solve different problems, and they behave differently the moment you push past the demo script.

1. Global life-sciences platforms

Veeva is the category. Built for multinational pharma with multi-country compliance regimes, medical affairs teams and regulated content governance. It is deeper and more rigorous than anything else here — and priced accordingly, at roughly ₹13,000 per user per month.

The mismatch is not quality, it is problem-fit. Veeva solves for regulatory defensibility across markets. An Indian domestic field force is solving for coverage against cycle target in a market where prescription data is not centrally available. Those need different instruments. You can configure Veeva toward the Indian model, but you are paying global enterprise rates and absorbing enterprise implementation effort to reach a starting point the domestic platforms ship with.

2. FMCG-heritage platforms with a pharma line

BeatRoute and FieldAssist both came up through distribution and consumer goods, and both now publish pharma offerings. BeatRoute positions across FMCG, liquor, consumer goods and pharma, bundling SFA with distributor management and a retailer engagement app. FieldAssist brings distribution and channel heritage to pharma coverage.

That lineage is a genuine advantage if you sell through both a prescription field force and a distribution channel — most pharma-only tools handle the channel side thinly. It is worth probing if you are purely prescription-led, because an architecture designed around outlets, SKUs and stock movement treats a doctor as a kind of outlet. The clarifying question for a demo: "Is a doctor a first-class object in your data model, or a type of outlet?" Then ask what happens to two years of prescription history when that doctor moves territory.

3. Pharma-native Indian platforms

SANeForce, SEFMED and RouteX were built inside Indian pharma and speak the vocabulary natively — RCPA, beat plans, chemist and stockist hierarchies, the DCR as Indian managers actually use it. This is where most domestic shortlists land, and where the differences are least visible from a feature grid, because everyone lists the same capabilities.

What separates them is not the feature list. It is what the system does with the data after it collects it — which is the subject of the next section.

Reporting, or deciding?

Almost every platform in this category is a reporting system. It collects what the field did and presents it back, accurately and on time. That was the right ambition when the alternative was paper.

It is no longer where the value sits. If a field force of 200 MRs generates forty thousand data points a cycle, the constraint is not capture — it is that no manager can read forty thousand rows and find the eleven that matter. A dashboard showing what happened is a more efficient version of the same problem.

The question worth asking every vendor on your shortlist is not what do you record. It is: at what point in the cycle does your system tell a manager to do something differently, and what does it tell them to do?

Coverage is a loop, not a report

Coverage against target has three moments, and most systems only occupy the last one.

1. At planning. Before the cycle opens, every doctor grade carries a required visit frequency, and the tour plan is checked against it. A plan that under-covers core-grade prescribers is caught at submission, by a manager, not discovered in retrospect.
2. Mid-cycle. On day nine, the system knows that core coverage is running at 61% of required frequency, concentrated in two territories, and that the gap is still closable. It says so — to the person who can act on it — while there are working days left.
3. At closure. The cycle is measured against the target it was planned against, not against activity totals. The number that closes the cycle is the same number that opened it.

A system that only does the third is a reporting tool. It hands you an accurate account of a cycle you can no longer influence. The board asks why coverage slipped, and the honest answer is that nobody knew until it had.

Analysis, not just data

The same distinction applies to everything else the field generates. RCPA that stores competitor volumes is data. RCPA that tells you your share at a chemist has moved six points against a named competitor since a scheme launched is analysis. Expense records are data; expenses reconciled against recorded travel with the exceptions surfaced is analysis. Secondary sales ingested is data; secondary sales matched against the coverage that was supposed to drive it is analysis.

This is the axis on which the Indian category is currently separating, and it is worth weighting heavily in an evaluation — because the cost of getting it wrong is not a worse dashboard. It is another eighteen months of finding out about coverage gaps after the cycle that contained them has closed.

Platform overview

Two vendors here publish list pricing: BeatRoute and ourselves. The Veeva range comes from independent pricing analyses rather than Veeva's own rate card, and SANeForce, SEFMED and FieldAssist quote on request — which is normal for enterprise software, but does mean you cannot compare most of this category without getting on several calls first. BeatRoute's packs convert to roughly ₹750 and ₹1,100 per user; our tiers are ₹299, ₹599 and ₹1,099, published in rupees and billed quarterly or annually.

That price spread is worth pausing on. At the midpoint, Veeva runs roughly ₹13,000 per user per month. A 200-MR Indian field force would be looking at something near ₹2.6 crore a year before implementation. This is not a criticism of Veeva — you get an enormously capable regulated-industry platform for it. It is simply why the Indian mid-market does not buy it, and why a domestic category exists at all.

Capability comparison

These are the capabilities that separate platforms in practice — deliberately specific, because at the level of "does it have DCR" every product here looks identical. Each cell reports what the vendor states in public material.

What each platform is built for

Veeva — the global standard, and the ceiling

Veeva holds roughly 80% of the global pharma field-sales CRM market. If you work in pharma commercial anywhere in the world, this is the system you have probably used. It is deep on regulated-industry needs: medical affairs, multichannel engagement, content management through Vault, compliance rigour, and regional data residency including APAC.

Pricing is per named user, subscription only, with independent analyses putting it in the $120–$200 per user per month range and volume discounts at enterprise scale. Tiers run from an entry-level Essentials edition up to the full multichannel suite.

Where it fits in India: subsidiaries of multinationals whose parent has already standardised on it, and large Indian companies with meaningful export and regulated-market operations. Where it does not: a domestic field force running RCPA and beat plans, where you would pay global enterprise rates for a platform that does not speak the local vocabulary and would need customisation to do so.

BeatRoute

The most directly comparable platform on this list to what we build, and we would rather say so than bury it. BeatRoute combines SFA, distributor management and a retailer engagement app, and serves large field teams across pharma, FMCG, liquor and consumer goods.

Two published capabilities are worth calling out because they are unusual. It has a native RCPA workflow that validates prescription intent captured at the HCP visit against the associated chemist — matched to specific molecules and prescribing doctors. Paired onboarding of doctors and pharmacies links the two, so you can see which doctor drove which pharmacy pull. That is a more sophisticated description of RCPA than most of this category publishes.

It also publishes AI-driven visit planning that suggests visits based on doctor segmentation, historical touchpoints and required engagement frequency, prompting reps toward next-best visits. Plus digital detailing and sample tracking at the point of call.

If your requirement is prescription attribution — connecting a doctor's intent to actual pharmacy movement — BeatRoute and RouteX are the two platforms here that publish against it directly. The question to put to both of us is the same: show it live, on a real territory, mid-cycle.

SANeForce

One of the longest-established players in Indian pharma SFA, with a substantial install base built up over many years. The integration story is the reason to look at it. If your company already runs SAP or Tally, has a payroll system that needs to consume field attendance, and wants primary and secondary sales data flowing into one reporting layer, that is precisely the problem shape SANeForce publishes against. It covers tour planning, call reporting, expense monitoring and coverage analysis.

The trade-off common to any platform built for enterprise integration is the implementation effort that comes with it. Worth asking for a specific go-live timeline for a company of your size and system landscape.

SEFMED (Cuztomise)

Another long-standing name in the Indian market with a decent install base across India and abroad. Two published emphases genuinely matter in Indian conditions. First, multilingual reporting — relevant when MRs across states are not uniformly comfortable in English, and a real driver of whether field data gets entered accurately. Second, tour planning with create, modify, send, approve and reject flows — one of the few vendors to publish the approval step explicitly, which suggests managers are expected to actually gate plans.

FieldAssist

FieldAssist came up through FMCG distribution and brings that heritage to pharma, publishing coverage across doctors, pharmacies and channel partners together with territory tracking and distributor insights. If you sell through both a prescription field force and a distribution channel, or run OTC alongside ethical, that dual fluency is a genuine advantage — most pharma-only tools handle the channel side thinly. If you are purely prescription-led, some of that strength goes unused.

Zoulte RouteX

Ours, so apply the scepticism you would to any vendor describing itself.

RouteX was built around the loop described earlier rather than around the report at the end of it. Coverage targets are set per customer classification before the cycle opens, the tour plan is approved against those targets, deviation is surfaced mid-cycle to the manager who can act on it, and the cycle closes measured against the number it opened with. One target, carried from planning through to closure, rather than a plan in one place and a report in another.

The consequence we care about is narrow: a manager should learn that core-grade coverage is behind in week two, in a named territory, while there are working days left to redirect. Not in a month-end review of a cycle that has already closed.

Around that loop: tour plans with a real approval chain, RCPA captured at the chemist counter including competitor brands and active schemes and attributed back to the prescribing doctor — so a coverage gap can be read against the prescription movement it did or did not produce — geo-verified visit capture that keeps working through dead zones and syncs when signal returns, e-detailing included rather than sold as a module, expenses derived from recorded travel rather than typed at month end, and integration with attendance and leave so field days reconcile against HR records instead of being maintained twice.

The design bias throughout is toward telling a manager what to do next rather than showing them what happened. That is a choice with costs — RouteX is a younger platform than most on this list, without the decade of enterprise integration work behind the incumbents.

Pricing is published — ₹299, ₹599 and ₹1,099 per MR per month by tier, billed quarterly or annually — and onboarding, migration and setup are included rather than quoted separately. Typical go-live is 24 to 72 hours for a company moving off spreadsheets or a previous SFA.

Where RouteX is not the right answer: if your decision is driven by multi-country regulated compliance, or you need deep SAP-level ERP integration as the primary requirement, the platforms above are built for that and we are not going to pretend otherwise. On prescription attribution specifically, BeatRoute publishes a comparable capability — read their material alongside ours and make both of us demonstrate it rather than describe it.

The cost question nobody answers honestly

Quoted per-MR price is rarely what you pay. The gap sits in five places, and they are worth naming explicitly before you compare two quotes:

• Setup and configuration. Territory structures, doctor masters, beat plans and approval hierarchies have to be built. Sometimes included, sometimes a one-time fee that exceeds the first year of licences.
• Data migration. Moving doctor lists, historical DCRs and territory mappings off the old system. Ask specifically whether it is chargeable and who does the work.
• Training and onboarding. For MRs and separately for managers, who use a different part of the product entirely.
• Support tier. Whether response commitments cost extra, and what happens after go-live when the implementation team moves on.
• Integration. Usually the largest variable. Connecting ERP, payroll or secondary sales data is where enterprise implementations expand.

A practical way to compare: ask every vendor for a three-year total for your actual MR count, including all of the above, rather than a monthly per-user figure. The ranking often changes.

If you are switching rather than starting

Most companies reading this already run something. Switching costs concentrate in three places, none of them the licence fee.

Your data. Doctor masters with grades and territory mappings, historical DCRs, expense records. Ask whether the new vendor migrates it and in what formats they accept it — including photographs of registers, which is more common than vendors admit.

Your field force's habits. MRs who have learned one app resist another, and adoption failure is the most common way an SFA rollout quietly dies. Ask what proportion of a typical customer's MRs are actively filing within 30 days.

Your reporting continuity. If the new system starts from zero, you lose year-on-year comparison at exactly the moment the board is watching whether the switch worked.

The demo script that separates them

Run the same thirty minutes with every vendor. Ask them to show, not describe:

1. "Show me a doctor visit being filed during the visit." Time it. If it takes ninety seconds, your MRs will do it at 10pm from memory.
2. "Show me coverage against target for core-grade doctors, mid-cycle." Not month-end. Not activity totals. Deviation from plan with days remaining.
3. "Show me a manager rejecting a tour plan." Then show me what the MR sees.
4. "Show me an RCPA entry including a competitor brand and a scheme."
5. "Show me an expense claim derived from recorded travel, not typed in."
6. "What is the three-year total for our MR count, everything included?"
7. "How long until our MRs are actually filing, and what does that depend on?"

Vendors who can do all seven live are a short list. Vendors who move to a slide on question two are telling you something about how their product treats the difference between activity and coverage.

Shortlisting by the shape of your operation

• Multinational subsidiary, parent standardised globally — the decision is largely made for you.
• Heavy SAP or Tally footprint, integration is the priority — prioritise published integration depth.
• Field force across many language regions — prioritise multilingual reporting.
• Pharma plus FMCG or channel sales — prioritise distribution fluency.
• Coverage against target is the board's question — prioritise mid-cycle measurement and the approval chain.
• Under 100 MRs, cost-sensitive — prioritise published pricing and short onboarding. Opaque quotes and multi-month implementations hurt small teams disproportionately.

We wrote the longer evaluation framework separately — how to choose a pharma SFA tool — covering the ten capabilities to test and the red flags worth walking away from. If you want the numbers behind why unmeasured field activity costs what it does, that is in the cost of ghost visits.

Common questions